39.77USD+15.91%Mkt Cap: 4.19B USDP/E: —Last update: 2026-06-01
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small mole…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap4.19B USD
Enterprise Value3.18B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-167.79M USD
Revenue/Share—
Last Price39.77 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees154
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.65
PEG—
EV/EBITDA-16.10
EV/Revenue—
P/S—
P/B7.44
EPS (TTM)-1.66
EPS (Forward)-2.33
52W Range
12.1597% of range40.76
52W High40.76 USD
52W Low12.15 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.13%
ROA-30.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-143.82M USD
CapEx (TTM)256.00K USD
FCF Margin—
FCF Yield-2.16%
Net Debt-495.77M USD
Net Debt/EBITDA2.51
Balance Sheet
Debt/Equity0.01
Current Ratio22.61
Quick Ratio22.16
Book Value/Sh4.589 USD
Cash/Share4.643 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)43.67 USD
Target Range20.00 USD – 52.00 USD
# Analysts12
Ownership
Shares Out.107.59M
Float67.12M
Insiders0.45%
Institutions113.98%
Short Interest
Short Ratio7.9d
Short % Float13.61%
Short % Out.9.62%
Shares Short10.35M
Short (prev mo.)10.08M
Technical
SMA 5032.57 (+22.1%)
SMA 20024.40 (+63.0%)
Beta0.25
S&P 52W Chg27.94%
Avg Vol (30d)1.25M
Avg Vol (10d)964.70K
Technical Indicators
RSI (14)56.6
MACD0.2326
MACD Signal0.2281
MACD Hist.+0.0045
BB Upper37.34 USD
BB Middle33.67 USD
BB Lower30.00 USD
BB Width21.80%
ATR (14)1.619 USD
Vol Ratio (20d)0.62x